Danske Bank A S Invests $71.59 Million in Bristol Myers Squibb Company $BMY

Danske Bank A S purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, HoldingsChannel reports. The fund purchased 1,587,377 shares of the biopharmaceutical company’s stock, valued at approximately $71,591,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Gateway Investment Advisers LLC boosted its holdings in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after acquiring an additional 10,284 shares during the period. CWA Asset Management Group LLC raised its stake in shares of Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares during the period. Stephens Inc. AR lifted its holdings in Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after purchasing an additional 32,476 shares in the last quarter. Railway Pension Investments Ltd boosted its stake in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after purchasing an additional 40,300 shares during the period. Finally, Norges Bank purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at about $1,554,154,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Down 0.0%

BMY stock opened at $59.71 on Wednesday. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The stock has a market cap of $121.59 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company’s 50 day moving average is $58.47 and its 200 day moving average is $51.64.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on BMY shares. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. HSBC raised their price target on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday. Finally, Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.41.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: HSBC raised its price target on BMY from $53 to $60 and kept a “hold” rating, signaling improved near-term analyst sentiment (though the new PT offers only ~0.5% upside from current levels). Benzinga
• Positive Sentiment: BMY reported that its investigational candidate BMS-986278 advanced through a key heart safety study (Phase 1 update), reducing development risk for that program and supporting pipeline value upside if subsequent data are favorable. TipRanks: BMS-986278 Update
• Neutral Sentiment: Zacks published a piece framing BMY as a strong value stock based on style scores and valuation metrics — a reminder that some investors are viewing BMY as a defensive, income-oriented pick rather than a high-growth biotech. Zacks: Value Stock
• Neutral Sentiment: Recent market commentary notes BMY has slightly outperformed recent market returns, reflecting stability from its commercial portfolio and dividend profile rather than fresh catalysts. Yahoo Finance: Market Performance
• Neutral Sentiment: Analyst comparisons (Pfizer vs. BMY) highlight competition in oncology and pipeline-driven M&A/portfolio moves; these comparisons keep investor focus on relative pipeline strength and strategic deals. Zacks: PFE vs BMY

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.